Search

Your search keyword '"Sanz, Guillermo F."' showing total 483 results

Search Constraints

Start Over You searched for: Author "Sanz, Guillermo F." Remove constraint Author: "Sanz, Guillermo F."
483 results on '"Sanz, Guillermo F."'

Search Results

1. Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies

2. Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

3. Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study

4. The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes

5. Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies

6. Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes

7. Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee

8. Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia

10. Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors

11. Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7

12. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial

13. MDS-476 Sabatolimab (MBG453) Combination Treatment Regimens for Patients With Higher-Risk Myelodysplastic Syndromes (HR-MDS): The Myelodysplastic Syndromes Studies in the STIMULUS Immuno-Myeloid Clinical Trial Program

14. Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis

16. Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia

17. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes

18. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia

21. An Agenda to Advance Research in Myelodysplastic Syndromes: A TOP 10 Priority List From the First International Workshop in MDS

22. LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors

24. Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes

25. Bloodstream Infections in Adult Patients Undergoing Cord Blood Transplantation from Unrelated Donors after Myeloablative Conditioning Regimen

27. LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors

28. Effect of CD8+ Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies

29. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy

31. An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS)

32. Poster: MDS-476 Sabatolimab (MBG453) Combination Treatment Regimens for Patients With Higher-Risk Myelodysplastic Syndromes (HR-MDS): The Myelodysplastic Syndromes Studies in the STIMULUS Immuno-Myeloid Clinical Trial Program

34. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

35. Impact of Graft-versus-Host Disease Prophylaxis on Outcomes after Myeloablative Single-Unit Umbilical Cord Blood Transplantation

36. Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group

37. Significance of Increased Blastic-Appearing Cells in Bone Marrow Following Myeloablative Unrelated Cord Blood Transplantation in Adult Patients

38. Effect of donor–recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis

39. Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas

41. Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients

45. Incidence, Risk Factors, and Outcome of Cytomegalovirus Infection and Disease in Patients Receiving Prophylaxis with Oral Valganciclovir or Intravenous Ganciclovir after Umbilical Cord Blood Transplantation

46. Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival

47. Prognostic value of cytogenetics in adult patients with Philadelphia-negative acute lymphoblastic leukemia

49. Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents

50. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion

Catalog

Books, media, physical & digital resources